Gain an overview of sepiapterin’s distinct dual mechanism of action in phenylketonuria (PKU), highlighting how it increases phenylalanine hydroxylase (PAH) function and improves conversion of phenylalanine (Phe) to tyrosine (Tyr).
All resources
Access additional materials on phenylketonuria (PKU), including practical tools and educational content, below.
|
Topic
Year
▼ Sepiapterin is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system. Adverse events should also be reported to PTC Therapeutics at pharmacovigilance@ptcbio.com.
Registration conditions differ internationally; always consult local prescribing information and/or Summary of Product Characteristics before prescribing any products.
MED-ALL-PTC923-2500012 | September 2025
MED-ALL-PKU-2600113 | May 2026